| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer
|
Nozawa, Kazuki
|
|
|
24 |
3 |
p. e103
|
article
|
| 2 |
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply
|
Johnston, Stephen R D
|
|
|
24 |
3 |
p. e104
|
article
|
| 3 |
Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial
|
Strnad, Vratislav
|
|
|
24 |
3 |
p. 262-272
|
article
|
| 4 |
Access to new drugs in paediatric oncology: can we learn from the ongoing ONC201 saga?
|
André, Nicolas
|
|
|
24 |
3 |
p. 209-212
|
article
|
| 5 |
Accumulating long-term evidence for partial breast irradiation
|
Meattini, Icro
|
|
|
24 |
3 |
p. 198-199
|
article
|
| 6 |
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
|
Tolaney, Sara M
|
|
|
24 |
3 |
p. 273-285
|
article
|
| 7 |
Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial
|
Walter, Thomas
|
|
|
24 |
3 |
p. 297-306
|
article
|
| 8 |
Cancer no longer a priority for England?
|
The Lancet Oncology,
|
|
|
24 |
3 |
p. 195
|
article
|
| 9 |
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial
|
Pignata, Sandro
|
|
|
24 |
3 |
p. 286-296
|
article
|
| 10 |
Concerns about alarmist portrayal of CT scans
|
McCollough, Cynthia H
|
|
|
24 |
3 |
p. e105
|
article
|
| 11 |
Correction to Lancet Oncol 2022; 23: 1031–43
|
|
|
|
24 |
3 |
p. e106
|
article
|
| 12 |
De-escalation in low-risk, HER2-positive breast cancer
|
Geuna, Elena
|
|
|
24 |
3 |
p. 200-201
|
article
|
| 13 |
Early-stage classical Hodgkin lymphoma in children and adolescents: when can radiotherapy be safely omitted?
|
Mascarin, Maurizio
|
|
|
24 |
3 |
p. 196-197
|
article
|
| 14 |
Endometrial cancer: the individual approach
|
Powell, Melanie E
|
|
|
24 |
3 |
p. 201-203
|
article
|
| 15 |
Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop
|
Shankar, Lalitha K
|
|
|
24 |
3 |
p. e133-e143
|
article
|
| 16 |
Helping patients with cancer in Türkiye and Syria
|
Das, Manjulika
|
|
|
24 |
3 |
p. e107
|
article
|
| 17 |
International Atomic Energy Agency safety missions to Fukushima
|
Das, Manjulika
|
|
|
24 |
3 |
p. 207
|
article
|
| 18 |
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
|
Choueiri, Toni K
|
|
|
24 |
3 |
p. 228-238
|
article
|
| 19 |
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium
|
Kroeze, Stephanie G C
|
|
|
24 |
3 |
p. e121-e132
|
article
|
| 20 |
Modernising the US FDA's Accelerated Approval pathway
|
Benjamin, David J
|
|
|
24 |
3 |
p. 203-205
|
article
|
| 21 |
NICE approves routine NHS use of CAR-T for diffuse large B-cell lymphoma
|
Wilkinson, Emma
|
|
|
24 |
3 |
p. 208
|
article
|
| 22 |
Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis
|
Mehanna, Hisham
|
|
|
24 |
3 |
p. 239-251
|
article
|
| 23 |
Quality control and childhood cancer medicines
|
The Lancet Oncology,
|
|
|
24 |
3 |
p. 195
|
article
|
| 24 |
Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study
|
Mauz-Körholz, Christine
|
|
|
24 |
3 |
p. 252-261
|
article
|
| 25 |
Sclerotic bone metastasis as initial manifestation of lung adenocarcinoma in a patient with SLE
|
Mittal, Ruchi
|
|
|
24 |
3 |
p. e144
|
article
|
| 26 |
Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent, and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group
|
Ehrhardt, Matthew J
|
|
|
24 |
3 |
p. e108-e120
|
article
|
| 27 |
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
|
Brown, Janet E
|
|
|
24 |
3 |
p. 213-227
|
article
|
| 28 |
US lawmakers call on Biden Administration to lower the price of enzalutamide
|
Furlow, Bryant
|
|
|
24 |
3 |
p. 206
|
article
|
Journal description